Editas Medicine (EDIT) grants 292,856 stock options to chief scientific officer

Rhea-AI Filing Summary

Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and expire on March 11, 2036.

The award was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this grant, Burkly holds 292,856 stock options from this award.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Burkly Linda

Role EVP, CHIEF SCIENTIFIC OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	292,856	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 292,856 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkly Linda

(Last) (First) (Middle)

11 HURLEY ST.

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.54	03/12/2026		A		292,856		(1)	03/11/2036	Common Stock	292,856	$0	292,856	D

Explanation of Responses:

1. This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030.

Remarks:

	/s/ Linda C. Burkly	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Editas Medicine (EDIT) disclose about Linda Burkly in this Form 4?

Editas Medicine disclosed that EVP and Chief Scientific Officer Linda Burkly received a stock option grant for 292,856 shares of common stock. The options were awarded as compensation and reported as an acquisition rather than an open-market purchase or sale.

What are the key terms of Linda Burkly’s new stock option grant at Editas Medicine (EDIT)?

The grant covers 292,856 shares of Editas Medicine common stock with an exercise price of $2.54 per share. The options expire on March 11, 2036, giving a long-dated incentive tied to the company’s future share performance over the coming years.

How does Linda Burkly’s Editas Medicine (EDIT) option grant vest over time?

The option granted to Linda Burkly vests over four years in equal monthly installments. Vesting starts on April 12, 2026 and continues through March 12, 2030, encouraging ongoing service and aligning her long-term incentives with Editas Medicine’s performance.

Is Linda Burkly’s Form 4 transaction at Editas Medicine (EDIT) a stock sale or purchase?

The Form 4 reports a compensation-related acquisition, not an open-market trade. Linda Burkly received a grant of stock options under code “A,” indicating a grant or award, with no shares bought or sold on the market in this specific transaction.

How many Editas Medicine (EDIT) options does Linda Burkly hold from this grant after the transaction?

Following this transaction, Linda Burkly holds 292,856 stock options from this grant. This reflects the full size of the reported award, as shown by the total derivative securities beneficially owned after the reported acquisition on the Form 4.